Selective TRH Receptor Ligands for CNS-Specific Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRH receptor subtypes in humans are indistinguishable, limiting the ability to differentiate between central nervous system (CNS) and pituitary-mediated biological effects of TRH, and existing compounds fail to selectively bind to the novel TRH receptor subtype in human CNS tissue.
Innovation Solution
The compound Glp-Asn-Pro-D-Tyr-DTrp-NH2 and its structurally related analogs demonstrate selective binding to a novel TRH receptor subtype in human CNS tissue, distinct from the TRH receptor in human pituitary tissue, allowing for discrimination between these subtypes and facilitating the development of therapeutic agents targeting CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional TRH compounds are used to treat CNS disorders, then therapeutic effects are achieved, but endocrine side effects occur due to inability to distinguish between CNS and pituitary receptor binding
Solution Approach 1:
The patent applies local quality by designing ligands with specific structural modifications (e.g., Glp-Asn-Pro-DTyr-DTrp-NH2) that confer selective affinity for CNS TRHR subtypes while reducing affinity for pituitary TRHR. This creates locally optimized binding properties that differentiate between two similar receptor types in different tissue locations, enabling CNS-specific therapeutic effects without pituitary-mediated endocrine side effects.
2Productivity
If TRH receptor binding studies are performed to identify therapeutic compounds, then compound screening is possible, but inability to distinguish between CNS and pituitary receptor subtypes limits identification of selective agents
Solution Approach 1:
The patent introduces discriminatory ligands as intermediaries that mediate between the screening process and the receptor subtypes. These ligands (e.g., Glp-Asn-Pro-DTyr-DTrp-NH2 and its analogs) serve as selective probes that bind preferentially to CNS TRHR subtypes, enabling researchers to distinguish CNS from pituitary receptors during compound screening. This intermediary approach transforms an indistinguishable system into a discriminable one, allowing precise identification of CNS-selective therapeutic compounds.
3Reliability
If existing TRH-based compounds are administered, then CNS therapeutic effects are achieved, but short half-life limits treatment duration and frequency
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TRH-based compounds (e.g., adding Glp- prefix, using D-amino acids, C-terminal modifications) to alter pharmacokinetic parameters while preserving CNS therapeutic effects. These structural modifications extend the half-life of the compounds, allowing for less frequent dosing and sustained therapeutic action in the CNS without compromising the selective binding to CNS TRHR subtypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This selective binding enables the identification of novel therapeutic compounds that can interact specifically with the CNS TRH receptor subtype, providing a means to understand and treat CNS disorders such as depression, epilepsy, and neurodegenerative diseases without endocrine side effects.
Implementation Method 1
Ligand-receptor interaction can be measured by radioligand binding studies... The receptors and ligand are incubated together until equilibrium is reached and the amount of labelled ligand bound to the receptors is determined.
Implementation Method 2
Competition binding assays, in which an unlabelled test compound is tested for its ability to displace the radiolabelled ligand, can be used to determine the affinity of such other compounds for the receptor site.
Data Source
AI summary
The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterize the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders.